Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, announced late-breaking data from the first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026 held in Boston. Field PULSE evaluates a novel high-voltage, sub-second pulsed field waveform delivered through Field Medical’s FieldForce Ablation System and Catheter, a focal, contact-sensing catheter, enabling instantaneous ablation through point-by-point energy delivery without reliance on prolonged tissue-catheter contact. The study was selected for a Late Breaking Clinical Trial presentation. By eliminating the need for sustained tissue-catheter contact, sub-second pulsed field delivery enables both efficient point-by-point ablation and individualized lesion sets.
Instantaneous energy delivery: Lesions created in less than 200 milliseconds, enabling rapid point-by-point ablation. Procedural efficiency: Median bilateral pulmonary vein isolation (PVI) time of 12.5 minutes, with the fastest case completed in 7.7 minutes. PVI durability: Remapping demonstrated progressive improvement in PVI durability with the optimized waveform. By vein: 94.2% By patient: 84.6%.
These findings extend Field Medical’s body of clinical evidence of its high-voltage focal PFA approach beyond ventricular arrhythmias and into the development of therapy for atrial fibrillation (AF). Together with previously reported six-month first-in-human VT data, the results support the emergence of a versatile ablation platform for all chambers of the heart. Bybit TradFi launched beginner-friendly account modes offering easy access to gold trading and zero fees, with the service powered by Infra Capital and available through the official Bybit app and website. These announcements illustrate a dual focus on advancing medical technology for complex cardiac arrhythmias and broadening access to traditional financial markets.
Leave a Reply